Status: Not yet recruiting
Efficacy/ Safety of Product CM9241GRU in Patients With Perennial Allergic Rhinitis
To evaluate the efficacy and safety of CM9241GRU versus placebo in the treatment of perennial allergic rhinitis.
Participants needed: 432
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Ache Laboratorios Farmaceuticos S.A.Updated: Aug 29, 2024
Eligibility criteria
Participants of both sexes aged 18 and over [+2]
Participants who have had nasal surgery in the six (6) months prior to the scree... [+7]